EMEA-000715-PIP05-13-M05
Key facts
| Invented name |
Otezla
|
| Active substance |
apremilast
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0353/2022
|
| PIP number |
EMEA-000715-PIP05-13-M05
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Behcet disease
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Amgen Europe B.V.
E-mail: medinfointernational@amgen.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|